PetrichorCapital Partners
PetrichorCapital Partners
Provides structured growth capital to facilitate the adoption of healthcare innovations
Petrichor Capital Partners makes structured investments across the global healthcare sector, with a focus on biopharmaceuticals, medical technology, diagnostics/tools, and tech-enabled services.
We provide growth investment solutions for late and commercial-stage companies.
We work with both public and private companies to support their long-term growth efforts and have deep experience with acquisitions, research & development activities, and commercial launches or expansions, among other situations.
Our investments enable leading healthcare innovators to reach the next stage of their evolution. Petrichor acts as a strategic advisor, partnering with management, Boards, and other investors to help ensure the success of our companies.
Petrichor Capital Partners in practice
Flexible Structures
Debt, equity and other structures tailored to a company’s needs.
High Growth Companies
Focused on late-stage or commercial public or private biopharma, medtech, and diagnostics companies, among others, providing capital for growth, M&A, and/or product development or launch, and beyond.
Enabling Long-Term Growth
Petrichor serves as value-added partner to execute long-term strategic vision.
Meet the team
The team has led over 125 investments, representing more than $6 billion of invested capital, and has sat on over 55 boards.
Meet the team
Portfolio
Discover the incredible companies that make up the Petrichor Capital Partners fund.
View portfolio
News
Read all newsAscend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities
November 2024
Read more on 
Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 2024
Read more on
Evergreen Theragnostics opens CCK2-VIEW, a Phase II small cell lung cancer clinical trial, in the European Union
October 2024
Read more on
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 2024
Read more on
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 2024
Read more on
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
October 2024
Read more on